Seeking Alpha

Galena Biopharma, Inc. EPS of -$0.46

  • Galena Biopharma, Inc. (GALE): Q4 EPS of -$0.46 may not be comparable to consensus of -$0.09.
  • Revenue of $1.3M misses by $0.32M.
  • Press Release
From other sites
Comments (22)
  • BioDoubt
    , contributor
    Comments (16) | Send Message
     
    Positive spin from DreamTeam in...3...2...1...
    17 Mar, 05:38 PM Reply Like
  • dakotadao
    , contributor
    Comments (22) | Send Message
     
    The headline should have read Gale revised sales forecast upward by 25% for 2014. Collected $7.5M more in cash since Dec 31, 2013.
    17 Mar, 05:42 PM Reply Like
  • Robert.from.Ct
    , contributor
    Comments (533) | Send Message
     
    You are correct

     

    However the shorts are trying to destroy the company and also a lot of investors who are long
    17 Mar, 05:51 PM Reply Like
  • MichaelJ8
    , contributor
    Comments (674) | Send Message
     
    from the 10k

     

    "As of December 31, 2013, Galena had cash and cash equivalents of $47.8 million, compared with $32.8 million as of December 31, 2012. As of March 14, 2014, Galena had cash and cash equivalents of $55.3 million."

     

    for those bad with math... thats 55.3-47.8$ million = 7.5$ million...how did they get that you ask?....

     

    They must REALLY like what they saw in the Q12014 sales for abstral!!!!

     

    The shorts only have so long before GALE skyrockets... sadly tomorrow GALE will be down... this makes me a sad clown.. but I will buy more
    17 Mar, 07:18 PM Reply Like
  • vanebfbc
    , contributor
    Comments (91) | Send Message
     
    Sometimes, I do think SA news editors pick a side before publishing news, so we only see half of the story. What about the raised guidance? What about the initiation of new development pathways and Phase II/Phase III enrollment? What about the new member, who was a former SEC, in the board of directors?
    17 Mar, 05:55 PM Reply Like
  • Robert.from.Ct
    , contributor
    Comments (533) | Send Message
     
    You are correct

     

    The deck seems to be stacked against Gale shareholders

     

    Remember SA was caught with its pants down,so now they report earnings with a negative spin,which should have been positive if they read the entire earnings report
    17 Mar, 05:59 PM Reply Like
  • BioDoubt
    , contributor
    Comments (16) | Send Message
     
    Well in that case...why didn't the headline include any mention of the SEC investigation? Oops.
    17 Mar, 06:04 PM Reply Like
  • StepUp
    , contributor
    Comments (473) | Send Message
     
    The new member, who was a former SEC, in the board of directors was likely added due to the SEC investigation. His/her addition is not good news.
    17 Mar, 06:16 PM Reply Like
  • Bill Maurer
    , contributor
    Comments (5042) | Send Message
     
    Later post. Up now.
    17 Mar, 10:14 PM Reply Like
  • gatlingg
    , contributor
    Comments (380) | Send Message
     
    Do you really know of a SEC investigation or are you just parroting the talking points of those shorting the stock (who say there should be an SEC investigation)
    If such an investigation were to occur we might not learn of it for months or perhaps never because nothing substantive was discovered. If you bothered to read the transcript you would have noticed that the appointment of the former securities enforcement officer to the BOD seemed to be in response to the law suits that have been filed and yes I think his addition is good news because the company has been lax in several areas that could & should be tightened up.
    17 Mar, 06:50 PM Reply Like
  • BioDoubt
    , contributor
    Comments (16) | Send Message
     
    If you bothered to read the 10K that they filed you might have seen this:
    "In February 2014, we learned that the SEC is investigating certain matters relating to our company and an outside investor-relations firm that we retained in 2013. We have been in contact with the SEC staff through our counsel and are cooperating with the investigation."
    17 Mar, 06:56 PM Reply Like
  • MichaelJ8
    , contributor
    Comments (674) | Send Message
     
    is this an "official" investigation of GALE, or just an investigation of the relationship between DTG and GALE...

     

    either way, in the end, SEC will find no wrong doing on GALE's part.
    17 Mar, 07:28 PM Reply Like
  • arthurs1
    , contributor
    Comments (355) | Send Message
     
    Smack down!
    17 Mar, 09:45 PM Reply Like
  • arthurs1
    , contributor
    Comments (355) | Send Message
     
    Have you ever heard of an unofficial SEC investigation?
    It's kind of like being a little bit pregnant.
    17 Mar, 09:47 PM Reply Like
  • MichaelJ8
    , contributor
    Comments (674) | Send Message
     
    well... I just trying to clarify what the SEC is investigating really,, but I suppose this whole thing is about if GALE should be held accountable at any length for DTG actions of not having their authors properly use disclaimers...

     

    Its all garbage anyway. GALE all the way,,,, this DTG stuff is complete utter nonsense. I will not be chased away by bogus claims
    17 Mar, 09:59 PM Reply Like
  • mcss
    , contributor
    Comments (5) | Send Message
     
    Investment in this company is all about their cancer drug being approved after FDA Phase 3 testings. The investigations are just sideshows. I've been waiting for sometime to buy some below $3... Looks like tomorrow could be my lucky day. Thanks again guys!!
    17 Mar, 09:05 PM Reply Like
  • ICE8200
    , contributor
    Comments (4) | Send Message
     
    A great move for the shorts. They made $$$ going down. Then jumped on and made more as the stock went up. NICE !!!!!!!!!!!!!!!!!
    17 Mar, 09:37 PM Reply Like
  • BigSwingingRichard
    , contributor
    Comments (13) | Send Message
     
    $GALE has new ex-SEC enforcer on its board. But what about the Drugs. Thinking about using one in conjunction with Herceptin. Really? Herceptin does not need help. Saved loved ones life Oncologist dismissed any future marriage of Nuevax and Herceptin as non-sense and unnecessary. Just sayin....buy for other reasons or just buy Roche(Herceptin)
    17 Mar, 09:46 PM Reply Like
  • MichaelJ8
    , contributor
    Comments (674) | Send Message
     
    are you being serious? Herceptin works in 25% of those how survived breast cancer. There is a large market out there for something that targets patients where Herceptin doesn't work. It also is possible the combination could work better. There is no guarantee that ones cancer was homogeneous.

     

    You make a very weak point. Sorry, BigSwingingRichard with 1 comment. Have a nice day.
    17 Mar, 09:57 PM Reply Like
  • moyano254
    , contributor
    Comment (1) | Send Message
     
    Revenue of 1.3MIL?? Please explain where you got that from.
    17 Mar, 10:10 PM Reply Like
  • MichaelJ8
    , contributor
    Comments (674) | Send Message
     
    Revenue of 1.3 mil for 4Q... true. 2.5 million revenue for whole year, true. Read 10-k report or 8k.
    18 Mar, 12:42 AM Reply Like
  • maxcalvillo
    , contributor
    Comments (14) | Send Message
     
    Reporting the numbers just like every other stock. What did you expect ... management and creemteam's hype coming true for you like it did for themselves ?
    Management knew these numbers well in advance of the PUMP ! AND DOWN SHE GOES !
    18 Mar, 02:33 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector